Danimer Scientific Announces Third Quarter 2023 Results

-- PHA-Based Product Revenue Grows 58% vs. Prior Year --

-- Bid Awards Issued to Danimer Converter Partners for Nodax-Based Cutlery Require Approximately 20 million pounds of resin annually --

-- Reduced Guidance Reflects Changes in Customer Launches and Timing of First Shipments --

BAINBRIDGE, Ga.--()--Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading next-generation bioplastics company focused on the development and production of highly engineered biodegradable materials, today announced financial results for its third quarter, ended September 30, 2023.

Stephen E. Croskrey, Chairman and Chief Executive Officer of Danimer, commented, “We are excited to announce that new business awards associated with a large Quick Service Restaurant program for Nodax-based biodegradable cutlery have been issued to several of our converter partners. Total demand for our product is expected to be approximately 20 million pounds per year at full run-rate, with first shipments expected to begin in the second half of next year. With these cutlery awards, we've now opened another significant product category for our PHA-based resins, which further validates our product in the marketplace and will continue to drive volume across our manufacturing assets.”

Mr. Croskrey continued, “While our sales expectations for the second half of 2023 were adversely impacted by timing delays among several anticipated commercial programs, we believe our work with our commercial partners on these programs is nearly complete and look forward to products launching throughout 2024. We’re pleased to be working with several major brands and share in their commitment to ensuring that each launch transitioning products and packaging from traditional petroleum-based plastics to a more sustainable material is both seamless and an unqualified success. While the time and resources to complete these final steps are proving to be more extensive than we had previously anticipated, particularly with respect to certain novel end-use applications, we are more confident than ever that these launches will enable enduring success. Our materials enable brands to differentiate competitively, extend their environmental leadership roles, and enhance their reputations for sustainability.”

Mr. Croskrey concluded, “Each product launch is generating strong interest from and opportunity to engage with new commercial partners seeking long-term solutions to plastic waste across multiple product categories and industries. While we are disappointed our near-term financial expectations were not met, we view this as a temporary delay and retain our conviction that we are on the right path toward filling our existing capacity and continuing to make progress on our planned footprint expansion strategy.”

Third Quarter 2023 Financial Highlights:

  • Revenues in the third quarter grew to $10.9 million compared to $10.4 million in the year-ago quarter. Strong growth in sales of PHA-based products, which represented 78% of total revenue this quarter compared to 51% in the third quarter of last year, offset expected year-over-year declines in other areas. PLA-based resin sales decreased by $1.8 million relative to last year as a result of business interrupted by the Ukraine conflict. Service revenue in the third quarter was $0.5 million as compared to $1.3 million last year, the continuing result of the successful completion of development work for certain customers now progressing to commercialization.
  • Gross profit in the third quarter was $(7.7) million compared to $(4.1) million in the third quarter of 2022. Adjusted gross profit was $(2.6) million compared to $(1.5) million in the third quarter of last year. The reduction in adjusted gross profit primarily reflects increased fixed production costs associated with greater capacity.
  • Third quarter net loss was $(40.2) million this year compared to a net loss of $(94.9) million last year, primarily reflecting a non-recurring, non-cash goodwill impairment charge of $62.7 million in the prior year.
  • Adjusted EBITDA was $(9.3) million in the third quarter of 2023 compared to $(12.9) million in the third quarter of 2022. The ongoing improvement in adjusted EBITDA primarily reflects the Company’s comprehensive program of expense control measures.

Capital Structure

At September 30, 2023, the Company reported a total debt balance of $379.9 million, including approximately $45.7 million dollars of low-interest New Markets Tax Credit loans that the Company expects will be forgiven between 2026 and 2029. At September 30, 2023, cash and cash equivalents and restricted cash, which is primarily held to satisfy future interest payments, totaled $91.9 million.

Outlook

The Company’s previous full-year adjusted EBITDA guidance range was based on expected strong second half revenue growth through new customer product launches and associated first shipments that did not materialize as planned. Accordingly, the Company has modified its full-year 2023 adjusted EBITDA guidance to a range of $(40) million to $(37) million and will look forward to finalizing a number of expected product launches in 2024. Separately, the Company now anticipates full-year capital expenditures in the range of $27 million to $29 million, which is a revision toward the more favorable end of its wider previous range.

Webcast & Conference Call

A webcast and conference call will be held today, November 14, at 4:30 p.m. Eastern Time to review the Company’s third quarter results, discuss recent events and conduct a question-and-answer session. The live webcast of the conference call can be accessed on the Investor Relations section of the Company’s website at https://ir.danimerscientific.com.

For those unable to access the webcast, the conference call will be accessible domestically or internationally, by dialing 1-888-886-7786 or 1-416-764-8658, respectively. Upon dialing in, please request to join the Danimer Scientific Third Quarter 2023 Earnings Conference Call. The archived webcast will be available for replay on the Company's website after the call.

About Danimer Scientific

Danimer is a pioneer in creating more sustainable, more natural ways to make plastic products. For more than a decade, its renewable and sustainable biopolymers have helped create plastic products that are biodegradable and compostable and return to nature instead of polluting our lands and waters. Danimer’s technology can be found in a vast array of plastic end products that people use every day. Applications for its biopolymers include additives, aqueous coatings, extrusion coating, fibers, filaments, films and injection-molded articles, among others. Danimer holds more than 480 granted patents and pending patent applications in more than 20 countries for a range of manufacturing processes and biopolymer formulations. For more information, please visit https://danimerscientific.com.

Forward-Looking Statements

Please note that this press release may use words such as “appears,” “anticipates,” “believes”, “plans,” “expects,” “intends,” “future”, and similar expressions which constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding our expectations for full year 2023 capital expenditures, Adjusted EBITDA and cash balances. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve a number of risks and uncertainties. We caution that forward-looking statements are not guarantees and that actual results could differ materially from those expressed or implied in the forward-looking statements. Potential risks and uncertainties that could cause the actual results of operations or financial condition of the Company to differ materially from those expressed or implied by forward-looking statements in this release include, but are not limited to, the overall level of consumer demand on our products; general economic conditions and other factors affecting consumer confidence, preferences, and behavior; disruption and volatility in the global currency, capital, and credit markets; the financial strength of the Company's customers; the Company's ability to implement its business strategy, including, but not limited to, its ability to expand its production facilities and plants to meet customer demand for its products and the timing thereof; risks relating to the uncertainty of the projected financial information with respect to the Company; the ability of the Company to execute and integrate acquisitions; changes in governmental regulation, legislation or public opinion relating to our products; the Company’s exposure to product liability or product warranty claims and other loss contingencies; disruptions and other impacts to the Company’s business, as a result of the COVID-19 global pandemic and government actions and restrictive measures implemented in response; stability of the Company’s manufacturing facilities and suppliers, as well as consumer demand for our products, in light of disease epidemics and health-related concerns such as the COVID-19 global pandemic; the impact on our business, operations and financial results from the ongoing conflict in Ukraine; the impact that global climate change trends may have on the Company and its suppliers and customers; the Company's ability to protect patents, trademarks and other intellectual property rights; any breaches of, or interruptions in, our information systems; the ability of our information technology systems or information security systems to operate effectively, including as a result of security breaches, viruses, hackers, malware, natural disasters, vendor business interruptions or other causes; our ability to properly maintain, protect, repair or upgrade our information technology systems or information security systems, or problems with our transitioning to upgraded or replacement systems; the impact of adverse publicity about the Company and/or its brands, including without limitation, through social media or in connection with brand damaging events and/or public perception; fluctuations in the price, availability and quality of raw materials and contracted products as well as foreign currency fluctuations; our ability to utilize potential net operating loss carryforwards; and changes in tax laws and liabilities, tariffs, legal, regulatory, political and economic risks. More information on potential factors that could affect the Company's financial results is included from time to time in the Company's public reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. All forward-looking statements included in this press release are based upon information available to the Company as of the date of this press release, and speak only as of the date hereof. We assume no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release.

Danimer Scientific, Inc.
Condensed Consolidated Balance Sheets

 

 

September 30,

 

December 31,

(in thousands, except share and per share data)

 

2023

 

2022

Assets:

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

77,393

 

 

$

62,792

 

Accounts receivable, net

 

 

12,422

 

 

 

17,989

 

Other receivables, net

 

 

715

 

 

 

1,635

 

Inventories, net

 

 

26,685

 

 

 

32,743

 

Prepaid expenses and other current assets

 

 

4,754

 

 

 

5,225

 

Contract assets, net

 

 

5,103

 

 

 

4,687

 

Total current assets

 

 

127,072

 

 

 

125,071

 

 

 

 

 

 

 

 

Property, plant and equipment, net

 

 

449,824

 

 

 

453,949

 

Intangible assets, net

 

 

78,660

 

 

 

80,941

 

Right-of-use assets

 

 

19,157

 

 

 

19,028

 

Leverage loans receivable

 

 

31,446

 

 

 

31,446

 

Restricted cash

 

 

14,461

 

 

 

1,609

 

Other assets

 

 

346

 

 

 

226

 

Total assets

 

$

720,966

 

 

$

712,270

 

 

 

 

 

 

 

 

Liabilities and Stockholders' Equity:

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

3,909

 

 

$

14,977

 

Accrued liabilities

 

 

5,899

 

 

 

5,001

 

Deferred revenue

 

 

438

 

 

 

-

 

Current portion of lease liability

 

 

3,337

 

 

 

3,337

 

Current portion of long-term debt, net

 

 

1,184

 

 

 

1,972

 

Total current liabilities

 

 

14,767

 

 

 

25,287

 

 

 

 

 

 

 

 

Private warrants liability

 

 

113

 

 

 

212

 

Long-term lease liability, net

 

 

21,965

 

 

 

22,114

 

Long-term debt, net

 

 

378,687

 

 

 

286,398

 

Deferred income taxes

 

 

-

 

 

 

200

 

Other long-term liabilities

 

 

1,153

 

 

 

447

 

Total liabilities

 

$

416,685

 

 

$

334,658

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

Common stock, $0.0001 par value; 200,000,000 shares authorized: 102,035,267 and 101,804,454 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively

 

$

10

 

 

$

10

 

Additional paid-in capital

 

 

718,958

 

 

 

676,250

 

Accumulated deficit

 

 

(414,687

)

 

 

(298,648

)

Total stockholders’ equity

 

 

304,281

 

 

 

377,612

 

Total liabilities and stockholders’ equity

 

$

720,966

 

 

$

712,270

 

Danimer Scientific, Inc.
Condensed Consolidated Statements of Operations

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

(in thousands, except share and per share data)

 

2023

 

2022

 

2023

 

2022

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Products

 

$

10,454

 

 

$

9,099

 

 

$

33,724

 

 

$

33,890

 

Services

 

 

494

 

 

 

1,349

 

 

 

2,015

 

 

 

4,004

 

Total revenue

 

 

10,948

 

 

 

10,448

 

 

 

35,739

 

 

 

37,894

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Costs and expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue

 

 

18,685

 

 

 

14,503

 

 

 

56,327

 

 

 

45,606

 

Selling, general and administrative

 

 

16,555

 

 

 

19,413

 

 

 

52,098

 

 

 

62,042

 

Research and development

 

 

6,883

 

 

 

7,947

 

 

 

21,667

 

 

 

24,469

 

Loss on sale of assets

 

 

64

 

 

 

-

 

 

 

234

 

 

 

1

 

Impairment of long-lived assets

 

 

-

 

 

 

63,491

 

 

 

-

 

 

 

63,491

 

Total costs and expenses

 

 

42,187

 

 

 

105,354

 

 

 

130,326

 

 

 

195,609

 

Loss from operations

 

 

(31,239

)

 

 

(94,906

)

 

 

(94,587

)

 

 

(157,715

)

Nonoperating income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

Gain on remeasurement of private warrants

 

 

132

 

 

 

1,607

 

 

 

99

 

 

 

8,614

 

Interest, net

 

 

(8,584

)

 

 

(553

)

 

 

(21,132

)

 

 

(2,197

)

Loss on loan extinguishment

 

 

-

 

 

 

(1,500

)

 

 

(102

)

 

 

(1,500

)

Other, net

 

 

-

 

 

 

240

 

 

 

-

 

 

 

324

 

Total nonoperating income (expense):

 

 

(8,452

)

 

 

(206

)

 

 

(21,135

)

 

 

5,241

 

Loss before income taxes

 

 

(39,691

)

 

 

(95,112

)

 

 

(115,722

)

 

 

(152,474

)

Income taxes

 

 

(468

)

 

 

236

 

 

 

(317

)

 

 

767

 

Net loss

 

$

(40,159

)

 

$

(94,876

)

 

$

(116,039

)

 

$

(151,707

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted net loss per share

 

$

(0.39

)

 

$

(0.94

)

 

$

(1.14

)

 

$

(1.50

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of shares used to compute:

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted net loss per share

 

 

102,025,684

 

 

 

101,199,195

 

 

 

101,953,827

 

 

 

100,993,068

 

Danimer Scientific, Inc.
Condensed Consolidated Statements of Cash Flows

 

 

Nine Months Ended

 

 

September 30,

(in thousands)

 

2023

 

2022

Cash flows from operating activities:

 

 

 

 

 

 

Net loss

 

$

(116,039

)

 

$

(151,707

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Stock-based compensation

 

 

42,227

 

 

 

42,398

 

Depreciation and amortization

 

 

22,005

 

 

 

13,172

 

Amortization of debt issuance costs

 

 

6,209

 

 

 

1,601

 

Accounts receivable reserves

 

 

(1,462

)

 

 

1,205

 

Inventory reserves

 

 

540

 

 

 

609

 

Amortization of right-of-use assets and lease liability

 

 

(278

)

 

 

(270

)

Loss on disposal of assets

 

 

234

 

 

 

1

 

Deferred income taxes

 

 

(199

)

 

 

(767

)

Loss on extinguishment of debt

 

 

102

 

 

 

1,500

 

Gain on remeasurement of private warrants

 

 

(99

)

 

 

(8,614

)

Contract asset reserve

 

 

-

 

 

 

1,215

 

Impairment of long-lived assets

 

 

-

 

 

 

63,491

 

Other

 

 

941

 

 

 

43

 

Changes in operating assets and liabilities

 

 

 

 

 

 

Accounts receivable

 

 

7,029

 

 

 

(1,747

)

Other receivables

 

 

555

 

 

 

2,724

 

Inventories, net

 

 

5,475

 

 

 

(14,271

)

Prepaid expenses and other current assets

 

 

1,816

 

 

 

1,749

 

Contract assets

 

 

(1,244

)

 

 

(2,019

)

Other assets

 

 

(119

)

 

 

(5

)

Accounts payable

 

 

(2,061

)

 

 

(4,642

)

Accrued liabilities

 

 

1,893

 

 

 

(5,037

)

Other long-term liabilities

 

 

706

 

 

 

3

 

Unearned revenue and contract liabilities

 

 

438

 

 

 

1,786

 

Net cash used in operating activities

 

 

(31,331

)

 

 

(57,582

)

Cash flows from investing activities:

 

 

 

 

 

 

Purchases of property, plant and equipment and intangible assets

 

 

(25,722

)

 

 

(133,632

)

Proceeds from sales of property, plant and equipment

 

 

18

 

 

 

55

 

Investment in leverage loan receivable related to NMTC financing

 

 

-

 

 

 

(18,037

)

Acquisition of Novomer, net of cash acquired

 

 

-

 

 

 

(14

)

Net cash used in investing activities

 

 

(25,704

)

 

 

(151,628

)

Cash flows from financing activities:

 

 

 

 

 

 

Proceeds from long-term debt

 

 

130,000

 

 

 

24,700

 

Cash paid for debt issuance costs

 

 

(33,296

)

 

 

(1,547

)

Principal payments on long-term debt

 

 

(12,437

)

 

 

(886

)

Proceeds from employee stock purchase plan

 

 

282

 

 

 

526

 

Employee taxes related to stock-based compensation

 

 

(61

)

 

 

-

 

Proceeds from exercise of stock options

 

 

-

 

 

 

215

 

Proceeds from issuance of common stock, net of issuance costs

 

 

-

 

 

 

79

 

Cost related to warrants

 

 

-

 

 

 

(55

)

Net cash provided by financing activities

 

 

84,488

 

 

 

23,032

 

Net increase (decrease) in cash and cash equivalents and restricted cash

 

 

27,453

 

 

 

(186,178

)

Cash and cash equivalents and restricted cash-beginning of period

 

 

64,401

 

 

 

286,968

 

Cash and cash equivalents and restricted cash-end of period

 

$

91,854

 

 

$

100,790

 

Non-GAAP Financial Measures

This press release includes the non-GAAP financial measures “Adjusted EBITDA”, “Adjusted gross profit” and "Adjusted gross margin". Danimer management views these metrics as a useful way to look at the performance of its operations between periods and to exclude decisions on capital investment and financing that might otherwise impact the review of profitability of the business based on present market conditions.

Adjusted EBITDA is defined as net income or loss plus net interest expense, income taxes, depreciation and amortization, as adjusted to add back certain charges or gains that Danimer may record each period such as remeasurement of private warrants, stock-based compensation expense, as well as non-recurring charges such as (i) asset disposal gains or losses as well as other significant gains or losses such as debt extinguishments and impairment of goodwill; (ii) legal settlements; or (iii) other discrete non-recurring items. Danimer believes these items are not considered an indicator of ongoing performance. Adjusted EBITDA is not a measure of performance defined in accordance with GAAP. The measure is used as a supplement to GAAP results in evaluating certain aspects of Danimer’s business, as described below.

Adjusted gross profit is defined as gross profit plus depreciation, stock-based compensation and nonrecurring items.

Adjusted gross margin is defined as adjusted gross profit divided by total revenue.

Danimer believes that each of Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin is useful to investors in evaluating the Company’s performance because each measure considers the performance of the Company’s operations, excluding decisions made with respect to capital investment, financing and other non-recurring charges as outlined in the preceding paragraph. Danimer believes these non-GAAP metrics offer additional financial information that, when coupled with the GAAP results and the reconciliation to GAAP results, provides a more complete understanding of its results of operations and the factors and trends affecting its business.

Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin should not be considered as an alternative to net income or loss as an indicator of its performance or as alternatives to any other measure prescribed by GAAP as there are limitations to using such non-GAAP measures. Although Danimer believes that Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin may enhance an evaluation of its operating performance based on recent revenue generation and product/overhead cost control because it excludes the impact of prior decisions made about capital investment, financing and other expenses, (i) other companies in Danimer’s industry may define Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin differently than Danimer does and, as a result, they may not be comparable to similarly titled measures used by other companies in its industry, and (ii) Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin exclude certain financial information that some may consider important in evaluating Danimer’s performance.

Danimer compensates for these limitations by providing disclosure of the differences between Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin and GAAP results, including providing a reconciliation to GAAP results, to enable investors to perform their own analysis of Danimer’s operating results. Because GAAP financial measures on a forward-looking basis are not accessible, and reconciling information is not available without unreasonable effort, reconciliations to GAAP financial measures are not provided for forward-looking non-GAAP measures. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.

Danimer Scientific, Inc.
Reconciliation of Adjusted EBITDA to Net Income (Loss) (Unaudited)

 

 

Three Months Ended September 30,

 

 

2023

 

2022

(in thousands)

 

 

 

 

 

 

Net loss

 

$

(40,159

)

 

$

(94,876

)

Stock-based compensation

 

 

14,324

 

 

 

14,305

 

Interest, net

 

 

8,584

 

 

 

553

 

Depreciation and amortization

 

 

7,253

 

 

 

4,585

 

Income taxes

 

 

468

 

 

 

(236

)

Gain on remeasurement of private warrants

 

 

(132

)

 

 

(1,607

)

Strategic reorganization and related

 

 

382

 

 

 

-

 

Litigation and other legal related

 

 

28

 

 

 

375

 

Loss on extinguishment of debt

 

 

-

 

 

 

1,500

 

Impairment of goodwill

 

 

-

 

 

 

62,663

 

Public company transition

 

 

-

 

 

 

35

 

Other, net

 

 

-

 

 

 

(240

)

Adjusted EBITDA

 

$

(9,252

)

 

$

(12,943

)

Reconciliation of Adjusted Gross Profit (Loss) to Gross Profit (Loss) (Unaudited)

 

 

Three Months Ended September 30,

 

 

2023

 

2022

(in thousands)

 

 

 

 

 

 

Total revenue

 

$

10,948

 

 

$

10,448

 

Cost of revenue

 

 

18,685

 

 

 

14,503

 

Gross loss

 

 

(7,737

)

 

 

(4,055

)

Depreciation

 

 

5,086

 

 

 

2,571

 

Stock-based compensation

 

 

2

 

 

 

22

 

Adjusted gross loss

 

$

(2,649

)

 

$

(1,462

)

 

 

 

 

 

 

 

Adjusted gross margin

 

 

-24.2

%

 

 

-14.0

%

 

Contacts

Investors
James Palczynski
Phone: 415-876-8429
ir@danimer.com

Media
Anthony Priwer
apriwer@daltonagency.com
Phone: 615-515-4891

Contacts

Investors
James Palczynski
Phone: 415-876-8429
ir@danimer.com

Media
Anthony Priwer
apriwer@daltonagency.com
Phone: 615-515-4891